Lifitegrast eye prep

Indications

Lifitegrast eye prep is used for: Dry Eye Disease

Adult Dose

Eye drop Dry Eye Disease Indicated for treatment of the signs and symptoms of dry eye disease (DED) Instill 1 gtt q12hr into each eye

Child Dose

<17 years: Safety and efficacy not established

Renal Dose

Administration

Ophthalmic Administration Drops are in single-use containers; discard the single-use container immediately after using in each eye Remove contact lenses before instilling eye drops; may be reinserted 15 minutes following administration

Contra Indications

Precautions

Pregnancy-Lactation

Pregnancy There are no available data regarding use in pregnant women to inform any drug-associated risks Animal data (IV administration) Lifitegrast administered daily by IV injection to rats, from premating through gestation day 17, caused an increase in mean preimplantation loss and an increased incidence of several minor skeletal anomalies at 30 mg/kg/day, representing 5,400-fold the human plasma exposure at the recommended human ophthalmic dose (RHOD) In rabbits, an increased incidence of omphalocele was observed at the lowest dose tested, 3 mg/kg/day (400-fold the human plasma exposure at the RHOD, based on AUC), when administered by IV injection daily from gestation days 7 through 19 Lactation There are no data on the presence of lifitegrast in human milk; systemic exposure to lifitegrast from ocular administration is low

Interactions

Adverse Effects

Side effects of Lifitegrast eye prep : >10% Instillation site irritation (5-25%) Dysgeusia (5-25%) Reduced visual acuity (5-25%) 1-10% Blurred vision (1-5%) Conjunctival hyperemia (1-5%) Eye irritation (1-5%) Headache (1-5%) Increased lacrimation (1-5%) Eye discharge (1-5%) Eye discomfort (1-5%) Eye pruritus (1-5%) Sinusitis (1-5%)

Mechanism of Action

The exact mechanism in dry eye disease is not known Binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein bound on leukocytes, and blocks the interactions of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1) ICAM-1 may be overexpressed in corneal and conjunctival tissues in dry eye disease; LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells